Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma

Furtado, Ruelan; Crawford, Michael; Sandroussi, Charbel

doi:10.1245/s10434-014-3511-2

Cited by 24 publications

(21 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, the conclusive role of adjuvant therapy following curative resection of HCC remains to be defined (Samuel et al 2009). Nevertheless, several adjuvant strategies have been tested in clinical trials, including systemic and intra-arterial chemotherapy, intraarterial radiolabeled lipiodol, TACE, acyclic retinoids, interferon, adoptive immunotherapy, autologous tumor vaccine, and, more recently, sorafenib (Xie et al 2012;Furtado et al 2014). Earlier adjuvant trials in HCC suffered from deficiencies, such as small case numbers, heterogeneous patient populations, and nonstandardized end points, resulting in a lack of consolidative evidence (Samuel et al 2009).…”

Section: Adjuvant Therapy After Surgical Resectionmentioning

confidence: 99%

Treatment of Liver Cancer

Liu

Chen

2015

Cold Spring Harb Perspect Med

282

198

View full text Add to dashboard Cite

Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer. Incidence of liver cancer varies geographically and parallels with the geographic prevalence of viral hepatitis. A number of staging systems have been developed, reflecting the heterogeneity of primary liver cancer, regional preferences, and regional variations in resectability or transplant eligibility. Multimodality treatments are available for this heterogeneous malignancy, and there are variations in the management recommendations for liver cancers across specialties and geographic regions. Novel treatment strategies have merged with the advance of new treatment modalities. This work focuses on reviewing the incidence, staging, and treatment of liver cancer.

show abstract

Section: Adjuvant Therapy After Surgical Resectionmentioning

confidence: 99%

Treatment of Liver Cancer

Liu

Chen

2015

Cold Spring Harb Perspect Med

282

198

View full text Add to dashboard Cite

show abstract

“…Two meta-analyses compared the outcomes of surgical resection in combination with I 131 lipiodol versus surgical resection alone [36, 40]. Both of them favored the combination therapy in terms of OS, DFS, and recurrence [36, 40].…”

Section: Surgical Resectionmentioning

confidence: 99%

Management of hepatocellular carcinoma: an overview of major findings from meta-analyses

Zhao

et al. 2016

Oncotarget

View full text Add to dashboard Cite

This paper aims to systematically review the major findings from meta-analyses comparing different treatment options for hepatocellular carcinoma (HCC). A total of 153 relevant papers were searched via the PubMed, EMBASE, and Cochrane library databases. They were classified according to the mainstay treatment modalities (i.e., liver transplantation, surgical resection, radiofrequency ablation, transarterial embolization or chemoembolization, sorafenib, and others). The primary outcome data, such as overall survival, diseases-free survival or recurrence-free survival, progression-free survival, and safety, were summarized. The recommendations and uncertainties regarding the treatment of HCC were also proposed.

show abstract

“…2 Unfortunately, recurrence after resection occurs in up to 80% of patients within five years following surgery, which together with concomitant hepatic decompensation, are the main causes of death. 3 Several adjuvant treatments including arterial infusional chemotherapy, 4 I 131 lipiodol, 5,6 and interferon 7,8 have been used. Unfortunately, the clinical use of these adjuvant therapies is either controversial or requires further evaluation.…”

Section: Introductionmentioning

confidence: 99%

A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma

Xu¹,

Wang²,

Kim

et al. 2015

OncoImmunology

View full text Add to dashboard Cite

Background & Aims: There is no generally accepted adjuvant therapy for hepatocellular carcinoma (HCC) after curative resection. Autologous cytokine-induced killer (CIK) cells therapy has been reported to improve outcomes of patients with HCC, but its role as an adjuvant therapy remains unclear. This study aimed to evaluate the efficacy and safety of CIK as an adjuvant therapy for HCC after curative resection.Methods: This is a single center, phase 3, open label, randomized controlled trial (RCT). Two hundred patients who were initially diagnosed with HCC of Barcelona Clinic Liver Cancer (BCLC) stage A or B, and underwent curative hepatectomy were randomly assigned to receive four cycles of CIK treatment (the CIK group, n D 100) or no treatment (the control group, n D 100). The primary outcome was time to recurrence. The secondary outcomes included disease-free survival (DFS), overall survival (OS) and adverse events.Results: All patients in the CIK group finished the treatment by protocol. The median time to recurrence (TTR) was 13.6 (IQR 6.5-25.2) mo in the CIK group and 7.8 (IQR 2.7-17.0) mo in the control group (p D 0.01). There were no significant differences between the groups in DFS and OS. All adverse events were grade 1 or 2. There were no significant differences in incidence between the two groups.Conclusions: Four cycles of CIK therapy were safe and effective to prolong the median TTR in patients with HCC after curative resection, but the treatment did not improve the DFS and OS.

show abstract

Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma

Cited by 24 publications

References 22 publications

Treatment of Liver Cancer

Treatment of Liver Cancer

Management of hepatocellular carcinoma: an overview of major findings from meta-analyses

A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma

Contact Info

Product

Resources

About